References
- McKay WF, Peckham SM, Badura JM. (2007). A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop 31:729–734
- Oh CS, Jung ST, Cho YJ, et al. (2015). Bone transport for reconstruction in benign bone tumors. Clin Orthop Surg 7:248–253
- Sandhu HS. (2003). Bone morphogenetic proteins and spinal surgery. Spine 28:S64–S73
- Schuckert KH, Jopp S, Osadnik M. (2011). The use of platelet rich plasma, bone morphogenetic protein-2 and different scaffolds in oral and maxillofacial surgery – literature review in comparison with own clinical experience. J Oral Maxillofac Res 2:e2
- Tressler MA, Richards JE, Sofianos D, et al. (2011). Bone morphogenetic protein-2 compared to autologous iliac crest bone graft in the treatment of long bone nonunion. Orthopedics 34:e877–e884
- Smucker JD, Rhee JM, Singh K, et al. (2006). Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 31:2813–2819
- Knox JB, Dai JM 3rd, Orchowski J. (2011). Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2. Spine 36:672–676
- Owens K, Glassman SD, Howard JM, et al. (2011). Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion. Eur Spine J 20:612–617
- Carragee EJ, Hurwitz EL, Weiner BK. (2011). A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11:471–491
- Fu R, Selph S, McDonagh M, et al. (2013). Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 158:890–902
- Simmonds MC, Brown JV, Heirs MK, et al. (2013). Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 158:877–889
- Lee JH, Lee EN, Chang BS, Lee CK. (2014). Acute intravenous injection toxicity study of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in rat. Asian Spine J 8:113–118
- Yoon BH, Esquivies L, Ahn C, et al. (2014). An activin A/BMP2 chimera, AB204, displays bone-healing properties superior to those of BMP2. J Bone Miner Res 29:1950–1959
- Allendorph GP, Read JD, Kawakami Y, et al. (2011). Designer TGFβ superfamily ligands with diversified functionality. PloS One 6:e26402
- Hoodless PA, Haerry T, Abdollah S, et al. (1996). MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell. 85:489–500
- Chen Y, Bhushan A, Vale W. (1997). Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase. Proc Natl Acad Sci USA 94:12938–12943
- Nishimura R, Kato Y, Chen D, et al. (1998). Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273:1872–1879
- Massague J, Weis-Garcia F. (1996). Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Cancer Surv 27:41–64
- Gray PC, Greenwald J, Blount AL, et al. (2000). Identification of a binding site on the type II activin receptor for activin and inhibin. J Biol Chem 275:3206–3212
- Zimmerman CM, Mathews LS. (1996). Activin receptors: cellular signalling by receptor serine kinases. Biochem Soc Symp 62:25–38